Drug Profile
Stampidine
Alternative Names: HI-113; PHI-113Latest Information Update: 27 Sep 2010
Price :
$50
*
At a glance
- Originator Parker Hughes Institute
- Developer Paradigm Pharmaceuticals; Parker Hughes Institute
- Class Antiretrovirals
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adenovirus infections; HIV-1 infections
Most Recent Events
- 16 Feb 2006 This compound appears to still be in active development
- 16 Oct 2003 A preclinical study has been added to the Viral Infections pharmacodynamics section
- 20 Nov 2002 Two studies have been added to the Viral infections antimicrobial activities section and one study has been added to the adverse events and pharmacokinetics sections ,